Bristol-Myers Squibb is to showcase new clinical data on its liver disease portfolio at the forthcoming annual meeting of the European Association for the Study of the Liver (EASL).
A total of 20 abstracts from the company's portfolio will be presented at the Barcelona event this month, including data on therapies such as daclatasvir, asunaprevir, Lambda, BMS-791325, brivanib and Baraclude.
Key presentations will include analysis of clinical trial data showing the benefits its direct-acting antivirals and Lambda can offer in the treatment of hepatitis C.
The information highlighted at EASL will help expand understanding of Bristol-Myers Squibb's new therapies and support their continuing clinical development.
Dr Brian Daniels, senior vice-president for global development and medical affairs at Bristol-Myers Squibb's research and development division, said: "Bristol-Myers Squibb is at the forefront of discovering, developing and delivering potential treatments for diseases of the liver where there remains considerable unmet medical need."
Last month, the company announced a new alliance with the Duke Translational Medicine Institute, focusing on the development of new therapies in areas such as idiopathic pulmonary fibrosis.